Table 4.
26-week treatment of exenatide versus insulin glargine, anthropometric-and biochemical parameters
| Exenatide (n = 11) | Insulin glargine (n = 12) | P between groups | ||||||
|---|---|---|---|---|---|---|---|---|
| Baseline | Follow-up | P | Baseline | Follow-up | P | Baseline | Follow-up | |
| BMI, kg m−2 | 29.0 ± 2.6 | 27.6 ± 3.1 | <0.01 | 29.9 ± 3.3 | 30.0 ± 3.6 | 0.80 | 0.47 | <0.01 |
| Waist, cm | 108 ± 9 | 104 ± 10.3 | <0.01 | 109 ± 10 | 110 ± 10 | 0.53 | 0.79 | <0.01 |
| Biochemical measurements (in fasten state) | ||||||||
| HbA1c, % | 7.7 ± 1.7 | 7.1 ± 1.9 | <0.01 | 7.5 ± 0.8 | 6.8 ± 0.7 | <0.01 | 0.68 | 0.49 |
| Plasma glucose, mmol L−1 | 10.4 ± 3.7 | 9.5 ± 4.0 | 0.14 | 9.3 ± 1.6 | 7.1 ± 1.2 | <0.01 | 0.36 | 0.03 |
| Total cholesterol, mmol L−1 | 4.1 ± 1.2 | 3.8 ± 0.9 | 0.04 | 4.3 ± 0.9 | 4.1 ± 0.9 | 0.06 | 0.74 | 0.25 |
| HDL cholesterol, mmol L−1 | 0.9 (0.7–1.2) | 0.9 (0.8–1.2) | 0.92 | 1.0 (0.9–1.1) | 1.0 (1.0–1.1) | 0.29 | 0.54 | 0.24 |
| LDL cholesterol, mmol L−1 | 1.9 ± 1.1 | 1.8 ± 0.9 | 0.22 | 2.5 ± 0.7 | 2.4 ± 0.8 | 0.17 | 0.17 | 0.65 |
| Triglycerides, mmol L−1 | 1.8 (1.0–3.0) | 1.2 (0.9–1.7) | 0.04 | 1.8 (1.1–2.1) | 1.4 (0.9–1.6) | 0.11 | 0.87 | 0.33 |
| Non-esterified fatty acids, mmol L−1 | 0.6 ± 0.1 | 0.5 ± 0.2 | 0.27 | 0.5 ± 0.1 | 0.4 ± 0.1 | 0.09 | 0.09 | 0.48 |
| eGRF (MDRD), mL min−1 1.73 m−2 | 90 ± 35 | 89 ± 26 | 0.65 | 82 ± 22 | 86 ± 26 | 0.29 | 0.52 | 0.37 |
| Albumin-to-creatinin ratio, g mol−1 | 0.7 (0.4–1.3) | 0.6 (0.4–0.7) | 0.88 | 1.5 (0.7–3.3) | 1.2 (0.7–3.5) | 0.14 | 0.09 | 0.31 |
Data are mean ± SD, median (interquartile range) or numbers of patients (percentage)
BMI body mass index, HbA1c hemoglobin A1c, HDL high-density lipoprotein, LDL low-density lipoprotein, eGFR estimated glomerular filtration rate, MDRD modification of diet in renal disease